UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Targeting interference of CTLA-4 co-inhibition to tumour specific T cells to enhance activity and reduce toxicity
  • Publication Type:
    Thesis/Dissertation
  • Authors:
    Roddie C
  • Date awarded:
    2016
  • Pagination:
    1, 154
  • Supervisors:
    peggs KS,pule MA,quezada SA
  • Status:
    Unpublished
  • Awarding institution:
    UCL (University College London)
  • Language:
    english
  • Date Submitted:
    25/04/2016
Abstract
Blockade of Cytotoxic T lymphocyte antigen-4 (CTLA-4) can enhance anti-tumour responses in preclinical models. A monoclonal antibody targeting human CTLA-4 (αCTLA4 mAb), is FDA approved for clinical use against metastatic melanoma. Paradigms suggest that αCTLA4 mAb blocks CTLA-4 dually on CTLA-4hi Tregs (restricting regulatory activity) and CTLA-4int-hi CD4 Teff (enhanced expansion) resulting in intratumoural Teff dominance and a net gain in anti-tumour activity. More recently, antibody-dependent cellular cytotoxicity (ADCC)-mediated depletion of CTLA-4hi Tregs in the tumour has been flagged as a critical factor driving anti-tumour immune responses. We explored the ADCC hypothesis in an adoptive cell transfer model of murine melanoma. We compared intratumoural Treg numbers in groups receiving CTLA-4+/+ or CTLA-4-/- tumour-specific T cells with/without exogenous αCTLA4 mAb. Exogenous αCTLA4 mAb resulted in diminished intratumoural tumour-specific Treg numbers in groups receiving CTLA-4+/+ but not CTLA-4-/- T-cells. Endogenous CTLA-4+/+ Tregs were depleted intratumourally with αCTLA4 mAb, irrespective of the CTLA-4 status of the adoptive cells. This data supports the proposed ADCC mechanism of αCTLA4 mAb and its dependence upon target cell CTLA-4 expression. Furthermore, we engineered tumour-specific T-cells to secrete αCTLA-4 mAb on IgG2a isotype (high ADCC activity) or IgG1 isotype (low ADCC activity) for adoptive transfer into melanoma-bearing mice. We found that transduced primary murine T-cells could engraft, infiltrate tumours and secrete biologically active αCTLA4 mAb. Secreted IgG2a αCTLA-4 mAb was strongly associated with intratumoural depletion of CTLA-4hi Tregs, but unexpectedly CTLA-4-replete transduced Teff were also vulnerable to depletion, and this significantly compromised the anti-tumour potential of this therapy. Intratumoural depletion of CTLA-4hi T-cells was not associated with (secreted) IgG1 αCTLA-4 mAb or (secreted) isotype control mAb. We believe that depletion of intratumoural Tregs is an important area for cancer immunotherapy, but our experience of αCTLA-4 mAb underlines the importance of careful immunomodulatory target selection to avoid toxicitiy.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers Show More
Editor
Research Department of Haematology
Editor
Research Department of Haematology
Editor
Research Department of Haematology
Author
Cancer Institute
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by